The FDA just approved Eli Lilly's Zepbound for sleep apnea — and Medicare coverage could be next
Eli Lilly (LLY) announced today that its blockbuster weight-loss drug Zepbound was approved by the U.S. Food and Drug Administration (FDA) as the first prescription drug to help alleviate moderate-to-severe obstructive sleep apnea (OSA) for adults with obesity.
Novo Nordisk (NVO) and Eli Lilly (LLY), the undisputed leaders in the global obesity drug market, saw their stocks heading in ...
GlobalData on MSN1d
FDA confirms end of Eli Lilly’s tirzepatide shortage after re-evaluationThe FDA declared the tirzepatide shortage over in October 2023, but a lawsuit by Outsourcing Facilities Association, a trade ...
Eli Lilly just gave investors several reasons to cheer.
The updates from clinical trials of Eli Lilly's competitors in the obesity market were largely underwhelming this year. See ...
Since pharmaceutical giant Eli Lilly (NYSE: LLY) reported earnings for the third quarter on Oct. 30, shares have been ...
What Eli Lilly ( LLY -0.05%) is doing is far more impressive. The company has been increasing its dividend at a high rate, ...
1don MSN
I Asked 3 Food Experts To Name the Best Peanut Butter—They All Said the Same Brand ...
After a stunning 703% run-up in price over the past five years, shares of Eli Lilly and Co. have been on a roller-coaster ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback